Fate of Liposomes In Vivo: Control Leading to Targeting

  • Gregory Gregoriadis
  • Judith Senior
  • Barbara Wolff
  • Christopher Kirby


It is well established (Gregoriadis, 1981) that following intravenous injection, liposomes and entrapped drugs are sooner or later taken up by the reticuloendothelial system (RES). Rate of uptake in particular tissues of the RES depends on vesicle size, surface charge and lipid composition, amount of liposomal lipid given, animal species and physiological state. For instance, a large vesicle size and/or a negative surface charge promote rapid uptake by tissues. Further, depending on the lipid composition of injected liposomes, plasma high density lipoproteins (HDL) will remove phospholipid molecules, destabilize vesicle structure and lead to entrapped drug release into the circulation. Thus, tissues will take up vesicles in various stages of destabilization and with a portion of their drug contents lost.


High Density Lipoprotein Total Phospholipid Mouse Plasma Small Unilamellar Vesicle Hepatic Parenchymal Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Allen, T.M., 1981, A study of phospholipid interaction between high density lipoprotein and small unilamellar vesicles, Biochim. Biophys. Acta, 640:385.Google Scholar
  2. Ashwell, G. and Moreli, A.G., 1976, The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins, Adv. Enzymol, 41:99.Google Scholar
  3. Gregoriadis, G., 1974, Structural requirements for the specific uptake of macromolecules and liposomes by target tissues, in: “Enzyme Therapy in Lysosomal Storage Diseases”, J.M. Tager, G.J.M. Hooghwinkel and W.Th. Daems, eds., North-Holland Publishing Co., Amsterdam.Google Scholar
  4. Gregoriadis, G., 1981, Targeting of drugs: Implications in medicine, The Lancet, 2:241.Google Scholar
  5. Gregoriadis, G., 1983, Targeting of drugs with molecules, cells and liposomes, TIPS, 4:304Google Scholar
  6. Gregoriadis, G., ed., 1984, “Liposome-Technology”, vols. I–III, CRC Press Inc., Boca Raton.Google Scholar
  7. Gregoriadis, G. and Davis, C., 1979, Stability of liposomes in-vivo and in-vitro is promoted by their cholesterol content and the presence of blood cells, Biochem. Biophys. Res. Comm., 89:1287.Google Scholar
  8. Gregoriadis, G. and Meehan, A., 1981, Interaction of antibody-bearing small unilamellar liposomes with antigen-coated cells: the effect of antibody and antigen concentration on the liposomal and cell surface respectively, Biochem. J., 200:211.Google Scholar
  9. Gregoriadis, G. and Neerunjun, D., 1975 Homing of liposomes to target cells, Bioche Biophys. Res. Comm., 65:537.CrossRefGoogle Scholar
  10. Gregoriadis, G. and Senior, J., 1980, The phospholipid component of small unilamellar liposomes controls the rate of clearance of entrapped solutes from the circulation, FEBS Lett., 119:43.PubMedCrossRefGoogle Scholar
  11. Gregoriadis, G. and Senior, J., 1984, Targeting of small unilamellar liposomes to the galactose receptor in-vivo, Biochem. Soc. Trans., 12:337.Google Scholar
  12. Gregoriadis, G., Neerunjun, D.E. and Hunt, R., 1977, Fate of a liposome-associated agent injected into normal and tumour-bearing rodents. Attempts to improve localization in tumour tissues, Life Sci., 21:357.Google Scholar
  13. Gregoriadis, G., Mah, M.M. and Meehan, A., 1981, Interaction of antibody-bearing small unilamellar liposomes with target free antigen in-vitro and in-vivo: Some influencing factors, Biochem. J., 200:203.Google Scholar
  14. Hashimoto, Y., Sugawara, M., Masuko, T. and Hojo, H., 1983, Anti-tumour effect of actinomycin D entrapped in liposomes bearing subunits of tumour-specific monoclonal immunoglobulin M antibody, Cancer Res., 43:5328.PubMedGoogle Scholar
  15. Heath, T.D., Fraley, R.T. and Papahadjopoulos, D., 1980, Antibody targeting of liposomes: Specific interaction of vesicles conjugated to anti-erythrocyte F(ab’)2, Science, 210:539.PubMedCrossRefGoogle Scholar
  16. Hwang, K.J., Luk, K-F.S. and Beaumier, P.L., 1980, Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: A kinetic study, Proc. Natl. Acad. Sci. USA, 77:4030.Google Scholar
  17. Kirby, C. and Gregoriadis, G., 1980, The effect of the cholesterol content of small unilamellar liposomes on the fate of their lipid components in-vivo, Life Sci., 27:2223.PubMedCrossRefGoogle Scholar
  18. Kirby, C. and Gregoriadis, G., 1981, Plasma-induced release of solutes from small unilamellar liposomes is associated with pore formation in the bilayers, Biochem. J., 199:251.Google Scholar
  19. Kirby, C. and Gregoriadis, G., 1983, The effect of lipid composition of small unilamellar liposomes containing melphalan and vincristine on drug clearance after injection into mice, Biochem. Pharmacol., 32:609.Google Scholar
  20. Kirby, C. and Gregoriadis, G., 1984a, A simple novel method for efficient drug entrapment in liposomes, in: “Liposome Technology”, Vol. I, G. Gregoriadis, ed., CRC Press Inc., Boca Raton.Google Scholar
  21. Kirby, C. and Gregoriadis, G., 1984b, Incorporation of Factor VIII into liposomes, in: “Liposome Technology”, Vol. II, G. Gregoriadis, ed., CRC Press Inc., Boca Raton.Google Scholar
  22. Kirby, C. and Gregoriadis, G., 1984c, Preparation of liposomes containing Factor VIII for oral treatment of haemophilia, J. Microencap., 1:33.CrossRefGoogle Scholar
  23. Kirby, C., Clarke, J. and Gregoriadis, G., 1980, Cholesterol content of small unilamellar liposomes controls phospholipid loss to high density lipoproteins in the presence of serum, FEBS Lett., 111:324.PubMedCrossRefGoogle Scholar
  24. Kirby, C., Clarke, J. and Gregoriadis, G., 1980, Effect of the cholesterol content of small unilamellar liposomes on their stability in-vivo and in-vitro, Biochem. J., 186:591.Google Scholar
  25. Krupp, L., Chobanian, A.V. and Brecher, I.P., 1976, The in-vivo transformation of phospholipid vesicles to a particle resembling HDL in the rat, Biochem. Biophys. Res. Commun., 72:1251.Google Scholar
  26. Martin, F.J. and Papahadjopoulos, D., 1982, Irreversible coupling of immunoglobulin fragments to preformed vesicles, J. Biol. Chem., 257:286.Google Scholar
  27. Mayhew, E. and Rustum, Y., 1983, Effect of liposome-entrapped chemo-therapeutic agents on mouse primary and metastatic tumours, Biol. Cell., 47:81.Google Scholar
  28. Moreli, A.G., Gregoriadis, G., Scheinberg, I.H., Hickman, J. and Ashwell, G., 1974, The role of sialic acid in determining the survival of glycoproteins in the circulation, J. Biol. Chem., 246:1461.Google Scholar
  29. van Oss, C.J., Gillman, CF., Bronson, P.M. and Border, J.JR., 1974, Phagocytosis-inhibiting properties of human serum alpha-1 acid glycoprotein, Immunol. Comm., 3:321.Google Scholar
  30. Patel, H.M., Tüzel, N.S. and Ryman, B.E., 1984, Inhibitory effect of cholesterol on the uptake of liposomes by liver and spleen, Biochim. Biophys. Acta, 761:142.Google Scholar
  31. Poste, G., 1983, Liposomes targeting in-vivo: Problems and opportunities, Biol. Cell., 47:19.Google Scholar
  32. Proffitt, R.T., Williams, L.E., Presant, C.A., Tin, G.W., Uliana, J.A., Gamble, R.C and Baldeschwielar, J.D., 1983, Liposomal blockade of the reticuloendothelial systems: Improved tumour imaging with small unilamellar vesicles, Science, 220:502.Google Scholar
  33. Scherphof, G., Roerdink, F., Waite, M. and Parks, I., 1978, Disintegration of phosphatidylcholine liposomes in plasma as a result of interaction with high density lipoproteins, Biochim. Biophys. Acta, 542:296.Google Scholar
  34. Scherphof, G., Damen, J. and Wilschut, J., 1984, Interactions of liposomes with plasma proteins, in: “Liposome Technology”, G. Gregoriadis, ed., CRC Press Inc., Boca Raton.Google Scholar
  35. Senior, J. and Gregoriadis, G., 1982a, Stability of small unilamellar liposomes in serum and clearance from the circulation: the effect of the phospholipid and cholesterol components, Life Sci., 30:2123.PubMedCrossRefGoogle Scholar
  36. Senior, J. and Gregoriadis, G., 1982b, Is half-life of circulating small unilamellar liposomes determined by changes in their permeability?, FEBS Lett., 145:109.PubMedCrossRefGoogle Scholar
  37. Senior, J. and Gregoriadis, G., 1984, Methodology in assessing liposomal stability in the presence of blood, clearance from the circulation of injected animals, and uptake by tissues, in: “Liposome Technology”, Vol. III, G. Gregoriadis, ed., CRC Press Inc., Boca Raton.Google Scholar
  38. Senior, J., Gregoriadis, G. and Mitropoulos, K., 1983, Stability and clearance of small unilamellar liposomes: Studies with normal and lipoprotein-deficient mice, Biochim. Biophys. Acta, 760:111.PubMedCrossRefGoogle Scholar
  39. Spanjer, H.H. and Scherphof, G., 1983, Targeting of lactosylceramide-containing liposomes to hepatocytes in-vivo, Biochim. Biophys. Acta, 734:40.Google Scholar
  40. Szoka, F. and Mayhew, E., 1983, Alteration of liposome disposition in-vivo by bilayer situated carbohydrates, Biochem. Biophys. Res. Commun., 110:140.Google Scholar
  41. Teradaira, R., Kolb-Bachofen, V., Schlepper-Schafer, J. and Kolb, H., 1983, Galactose-particle receptor on liver macrophages. Quantitation of particle uptake, Biochim. Biophys. Acta, 759:306.Google Scholar
  42. Toonen, P.A.H.M. and Crommelin, D.J.A., 1983, Immunoglobulins as targeting agents for liposome-encapsulated drugs, Pharm. Weekblad Scientific Edition, 5:269.Google Scholar
  43. Tümer, A., Kirby, C., Senior, J. and Gregoriadis, G., 1983, Fate of cholesterol-rich unilamellar liposomes containing 111In-labelled bleomycin after subcutaneous injection into rats, Biochim. Biophys. Acta, 760:119.Google Scholar
  44. Tyrrell, D.A. and Ryman, B.E., 1980, Liposomes: Bags of potential, Essays Biochem., 16:49.Google Scholar
  45. Wolff, B. and Gregoriadis, G., 1984, The use of monoclonal anti-Thy1, IgG1 for the targeting of liposomes to AKR-A cells in-vitro and in-vivo, Submitted.Google Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • Gregory Gregoriadis
    • 1
  • Judith Senior
    • 1
  • Barbara Wolff
    • 1
  • Christopher Kirby
    • 1
  1. 1.Division of Clinical SciencesClinical Research CentreMiddlesexUK

Personalised recommendations